康方生物授予济民可信依洛尤单抗注射液独家商业化权益

美股速递
Feb 03

康方生物宣布,已将其研发的依洛尤单抗注射液在中国大陆地区的独家商业化权利授予济民可信集团。此次合作将进一步拓展该创新药物在心血管疾病领域的市场覆盖,助力提升患者用药可及性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10